WAVE Life Sciences (WVE) Misses Q1 EPS by 23c, Revenues Miss

WAVE Life Sciences (NASDAQ: WVE) reported Q1 EPS of ($1.36), $0.23 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $3.03 million versus the consensus estimate of $10.97 million.

“Since the start of the year, we have made significant progress advancing suvodirsen, our lead clinical program for the treatment of Duchenne muscular dystrophy patients amenable to exon 51 skipping, and we look forward to providing dystrophin biopsy data in the second half of the year. In parallel, initial commercialization activities are underway to support the potential approval and launch of this investigational therapy, first in the United States and then globally,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. "Suvodirsen is the first of multiple development programs we intend to advance for Duchenne, potentially enabling us to reach more patients living with DMD. Beyond our Duchenne programs, we are advancing our differentiated PRECISION-HD clinical program, an allele-selective approach to treating Huntington’s disease, and we look forward to reporting topline clinical results from these HD studies by year-end.”

For earnings history and earnings-related data on WAVE Life Sciences (WVE) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Cushman & Wakefield names two capital markets leaders in APAC
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth